Assembly Biosciences Inc (NASDAQ:ASMB) saw a significant decline in short interest in April. As of April 30th, there was short interest totalling 1,406,200 shares, a decline of 41.0% from the April 15th total of 2,385,411 shares. Based on an average daily volume of 444,710 shares, the days-to-cover ratio is presently 3.2 days. Currently, 6.2% of the shares of the company are sold short.

Several equities analysts have recently weighed in on the company. BidaskClub cut Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, May 22nd. William Blair reiterated an “outperform” rating on shares of Assembly Biosciences in a research report on Friday, May 10th. Chardan Capital reiterated a “hold” rating and issued a $30.00 price target on shares of Assembly Biosciences in a research report on Monday, April 15th. Finally, Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Thursday, February 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Assembly Biosciences presently has a consensus rating of “Buy” and an average target price of $43.00.

Assembly Biosciences stock opened at $15.61 on Monday. Assembly Biosciences has a 52 week low of $13.13 and a 52 week high of $48.91. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.97 and a quick ratio of 7.97. The stock has a market cap of $398.84 million, a P/E ratio of -3.92 and a beta of 1.60.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.01. Assembly Biosciences had a negative return on equity of 56.45% and a negative net margin of 671.48%. The business had revenue of $3.89 million during the quarter, compared to analysts’ expectations of $3.81 million. As a group, equities research analysts predict that Assembly Biosciences will post -4.34 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Tibra Equities Europe Ltd purchased a new position in Assembly Biosciences during the first quarter worth about $918,000. New York State Common Retirement Fund grew its position in Assembly Biosciences by 15.3% during the fourth quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 3,100 shares in the last quarter. Victory Capital Management Inc. grew its position in Assembly Biosciences by 3.4% during the fourth quarter. Victory Capital Management Inc. now owns 530,909 shares of the biopharmaceutical company’s stock worth $12,009,000 after buying an additional 17,669 shares in the last quarter. Emerald Mutual Fund Advisers Trust grew its position in Assembly Biosciences by 13.3% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 418,143 shares of the biopharmaceutical company’s stock worth $8,233,000 after buying an additional 49,230 shares in the last quarter. Finally, Deutsche Bank AG grew its position in Assembly Biosciences by 29.8% during the fourth quarter. Deutsche Bank AG now owns 54,606 shares of the biopharmaceutical company’s stock worth $1,234,000 after buying an additional 12,525 shares in the last quarter. Institutional investors and hedge funds own 86.61% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2019/05/27/short-interest-in-assembly-biosciences-inc-asmb-drops-by-41-0.html.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

See Also: Futures Contract

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.